(Q45094881)

9 December 2017

title

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia (English)

1 reference

9 December 2017

0 references

1 reference

E. Lindström

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585844

25 May 2024

B. Eriksson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585844

25 May 2024

A. Hellgren

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585844

25 May 2024

L. von Knorring

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585844

25 May 2024

G. Eberhard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585844

25 May 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7585844

25 May 2024

publication date

1 May 1995

1 reference

full work available at URL

9 December 2017

https://api.elsevier.com/content/article/PII:0149291895801057?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

https://api.elsevier.com/content/article/PII:0149291895801057?httpAccept=text/plain

25 May 2024

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

25 May 2024

published in

Clinical Therapeutics

1 reference

9 December 2017

volume

17

1 reference

9 December 2017

issue

3

1 reference

9 December 2017

page(s)

402-412

1 reference

Risperidone: clinical safety and efficacy in schizophrenia

9 December 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Risperidone in the treatment of schizophrenia

25 May 2024

4

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

The positive and negative syndrome scale (PANSS) for schizophrenia

25 May 2024

6

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol

25 May 2024

8

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Five-factor model of schizophrenia. Initial validation

25 May 2024

9

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

The prediction of outcome in schizophrenia. I. Characteristics of outcome.

25 May 2024

12

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

25 May 2024

13

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

25 May 2024

14

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

25 May 2024

15

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes

25 May 2024

16

1 reference

https://api.crossref.org/works/10.1016/0149-2918(95)80105-7

25 May 2024

Identifiers

1 reference

9 December 2017

1 reference